Trials / Unknown
UnknownNCT04412408
Study on Sintilimab in Stage IV High Risk Neuroblastoma
Clinical Study on the Treatment of Recurrent Stage IV High Risk Neuroblastoma With Sintilimab
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Shanghai Children's Medical Center · Academic / Other
- Sex
- All
- Age
- 12 Months – 12 Years
- Healthy volunteers
- Not accepted
Summary
A phase I observational study on the safety and efficacy of treatment of recurrent stage IV high risk neuroblastoma with Nivolumab
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sintilimab | Sintilimab is administered every 21 days until the disease progresses or treatment is terminated due to unacceptable toxicity. For patients with clinical and radiologic benefits, treatment can last up to 2 years. Dose: 2 mg / kg intravenously for 60 min (± 10 min window) |
Timeline
- Start date
- 2020-09-01
- Primary completion
- 2022-12-31
- Completion
- 2023-06-30
- First posted
- 2020-06-02
- Last updated
- 2020-08-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04412408. Inclusion in this directory is not an endorsement.